Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M
about
Medicinal and injection therapies for mechanical neck disordersBotulinum toxin for subacute/chronic neck painBotulinum toxin for subacute/chronic neck painMedicinal and injection therapies for mechanical neck disordersRofecoxib for osteoarthritisMedicinal and Injection therapies for mechanical neck disordersGastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humansPharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugsTolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reportsNSAIDs: gastroprotection or selective COX-2 inhibitor?Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humansCOX-2 chronologyCyclooxygenase inhibition: between the devil and the deep blue seaManagement of peptic ulcer disease not related to HelicobacterSafety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring studyGastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal diseaseAcute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expressionSelective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxenAdvances in anti-inflammatory therapy.Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillanceUsing clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model processThe role of cyclooxygenase and lipoxygenase in cancer chemoprevention.Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectivesReview article: Helicobacter pylori infection in peptic ulcer haemorrhage.Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.Pathophysiology and first-line treatment of osteoarthritis.Rheumatoid arthritis: developing pharmacological therapies.Accounting for the increase in NSAID expenditure: substitution or leakage?Conventional treatments for ankylosing spondylitis.The double-edged sword of COX-2 selective NSAIDsNon-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritisInfluence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trialIncidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind studyWhat is the most effective therapy for preventing NSAID-induced gastropathy?
P2860
Q24188098-88AB870B-EE78-4769-921C-9A1E5998F6A6Q24188110-29697915-B648-479E-A53A-0B355F2C19E3Q24235339-6465AEE3-D64F-4FBD-8654-92214F4C1D71Q24243952-B4159089-C955-4605-A136-549694EC1111Q24244871-051D2A3C-23F3-4A69-AEBD-234BA29EE852Q24247212-5FD66DDD-CF61-4F5D-A72B-F8147641CD8BQ24669542-80299D45-4DDC-4F08-98AC-58D8B572B9D6Q24792554-8924E99E-5917-45CF-9EAC-81763FAF534CQ24816687-5A2C59E4-E871-4F64-BF42-F99DDF7B9844Q28168965-E1468B86-7B81-4AB2-A53A-2C685E3E290EQ28174827-51A371DE-E5BF-4A6D-8F17-25779CA53934Q28192719-41970C98-F3B6-4E53-9901-9777E3ADCAE7Q28192790-899791BA-83B9-4779-BFDD-420A40E6EFA9Q28192901-2160637A-0FA9-41D6-A676-EAB50E08F16EQ28194919-342439BA-881B-4003-AEB6-EBB972293665Q28196576-843C8162-9C27-4525-A0F1-EE70CEDF5633Q28196810-DB1791C1-4A62-4265-BCF4-DC6202BA63F5Q28196811-B3E9354E-3E43-4C90-B4AC-70810A0CC6DEQ28348645-4414EE89-01AF-43E2-A356-6B7810BEBA49Q33183500-DFA640EF-D553-401B-A7F8-A39BCA50A94EQ33516504-6FF811C4-EE7F-4354-B05E-3CF067B37865Q33907196-2DE0A0B3-F30A-483B-B8E7-93B86A523766Q34153217-4D354890-36FE-4A6A-86B1-F63E0B21B2EAQ34165468-D4056F89-9AE5-4699-93B8-3FEF6197C71FQ34340684-8245412B-1C6E-4594-9572-82D0DBC8311FQ34534365-4582899D-A111-44D0-89F8-40843BADB1CBQ34536718-404D180C-6311-4BA7-A7E9-492A8B63FC32Q34579637-26F6C089-4354-4111-A53D-435BD200B603Q34706975-EDF60EEC-D627-4F34-850C-9A55DC27D958Q34768089-383FE803-9223-4C89-AEFB-788171A0F90CQ34967537-589ABAC7-36CE-413E-959B-8C7E656F6ACCQ34994656-A88A0517-F694-4649-84E9-12BBAB45A575Q35083808-28B7B6C9-3E0D-4F93-A2F8-A7C8BF5E5A89Q35108309-55F0EB98-3D2D-4433-81E7-B29066478DEFQ35195182-05DF9AF6-1583-4251-BD46-5D1BE3CC9D30Q35555299-936A909F-52E1-4796-927D-0D19C5E222ABQ35594903-BA3E7A12-32EA-411F-B008-A434F300B981Q35594930-47B588BD-FF4F-4CFC-9617-059745E6456BQ35595723-8F82ED55-5C2C-42B2-9D09-6458521F3244Q35598100-A96B5299-E9E7-47C0-A4B4-140A2BB5785D
P2860
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Comparison of the effect of ro ...... xib Osteoarthritis Endoscopy M
@en
Comparison of the effect of ro ...... xib Osteoarthritis Endoscopy M
@nl
type
label
Comparison of the effect of ro ...... xib Osteoarthritis Endoscopy M
@en
Comparison of the effect of ro ...... xib Osteoarthritis Endoscopy M
@nl
prefLabel
Comparison of the effect of ro ...... xib Osteoarthritis Endoscopy M
@en
Comparison of the effect of ro ...... xib Osteoarthritis Endoscopy M
@nl
P2093
P921
P1476
Comparison of the effect of ro ...... xib Osteoarthritis Endoscopy M
@en
P2093
Beaulieu A
Bolognese J
Maldonado-Cocco J
Mortensen E
P304
P356
10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D
P577
2000-02-01T00:00:00Z